Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:52:55.479Z.
Calculation as of: 2026-10-06T18:52:55.479Z.
Quote observation: 2026-10-06T18:49:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92121ceff5fa8810ba44f4cfbc32d43134c549094e5f0bfbc79a82dde622c70d
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$3.25M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Revelation Biosciences, Inc. (REVB) | $2.97M | N/A | N/A | N/A | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.03M | N/A | N/A | N/A | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.10M | N/A | N/A | N/A | N/A |
| Universe Pharmaceuticals Inc. (UPC)vs › | $2.80M | N/A | N/A | N/A | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.20M | N/A | N/A | N/A | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.21M | N/A | N/A | N/A | N/A |
| iSpecimen Inc. (ISPC)vs › | $2.72M | N/A | N/A | N/A | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.24M | N/A | N/A | N/A | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.25M | N/A | N/A | N/A | N/A |
| Nuwellis, Inc. (NUWE)vs › | $2.62M | N/A | 0.58 | 0.58 | 0.58 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.76
Forward EPS (Est.)
$-5.18
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2024-05-10 | 0.81 |
| 2024-05-09 | 0.86 |
| 2024-05-08 | 0.87 |
| 2024-05-07 | 0.93 |
| 2024-05-06 | 0.92 |
| 2024-05-03 | 0.93 |
| 2024-05-02 | 0.92 |
| 2024-05-01 | 0.84 |
| 2024-04-30 | 0.83 |
| 2024-04-29 | 0.83 |
| 2024-04-26 | 0.85 |
| 2024-04-25 | 0.84 |
| 2024-04-24 | 0.82 |
| 2024-04-23 | 0.81 |
| 2024-04-22 | 0.80 |
| 2024-04-19 | 0.88 |
| 2024-04-18 | 0.88 |
| 2024-04-17 | 0.84 |
| 2024-04-16 | 0.75 |
| 2024-04-15 | 0.72 |
| 2024-04-12 | 0.82 |
| 2024-04-11 | 0.91 |
| 2024-04-10 | 0.91 |
| 2024-04-09 | 0.95 |
| 2024-04-08 | 1.02 |
| 2024-04-05 | 1.05 |
| 2024-04-04 | 1.07 |
| 2024-04-03 | 1.02 |
| 2024-04-02 | 1.02 |
| 2024-04-01 | 1.04 |
| 2024-03-28 | 1.07 |
| 2024-03-27 | 0.95 |
| 2024-03-26 | 1.02 |
| 2024-03-25 | 0.94 |
